Effect of Cyproterone acetate in patients with Benign Prostatic Hypertrophy

Determination of Cyproterone acetate effect to prevent recurrent urinary retention in patients with Benign Prostatic Hypertrophy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181106041572N1

Enrollment

Registered

2019-04-30

Start date

2019-04-09

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hypertrophy. Enlarged prostate

Interventions

Intervention 1: Intervention group:Patients who complained of acute urinary retention are referred to the Urology Emergency Department of Quaem Hospital with primary BPH diagnosis After insertion of a

Eligibility

Sex/Gender

Male

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with acute urinary retention complaints with initial diagnosis of BPH.

Exclusion criteria

Exclusion criteria: Prostate cancer Urinary infections Use of sympathomimetic drugs

Design outcomes

Primary

Measure	Time frame
Urinary retention. Timepoint: checking of urinary retention immediately after removal of urinary catheter 7 days after starting of cyproterone acetate with ureteral catheter and re-examination one week and 4 weeks after it and follow up to 6 months later. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Korooji

Mashhad University of Medical Sciences

karojia941@mums.ac.ir+98 51 3868 9405

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026